Effects of α-tocopherol and β-carotene supplementation on cancer incidence and mortality: 18-Year postintervention follow-up of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 178-185

  Virtamo, Jarmo ^a   Taylor, Phil R ^b   Kontto, Jukka ^a   Männistö, Satu ^a   Utriainen, Meri ^c   Weinstein, Stephanie J ^b   Huttunen, Jussi ^a   Albanes, Demetrius ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

cancer; mortality; post trial; tocopherol; carotene

Indexed keywords

CANCER; MORTALITY; POST-TRIAL; Α-TOCOPHEROL; Β-CAROTENE;

AGED; ALPHA-TOCOPHEROL; ANTIOXIDANTS; BETA CAROTENE; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84898944940     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28641     Document Type: Article

References (33)

1. Peto R, Doll R, Buckley JD, et al. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981; 290: 201-8.
2. Dorgan JF, Schatzkin A,. Antioxidant micronutrients in cancer prevention. Hematol Oncol Clin North Am 1991; 5: 43-68.
3. The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4: 1-10.
4. The ATBC Study Group. Incidence of cancer and mortality following α-tocopherol and β-carotene supplementation: a postintervention follow-up. JAMA 2003; 290: 476-85.
5. Korhonen P, Malila N, Pukkala E, et al. The Finnish Cancer Registry as follow-up source of a large trial cohort. Acta Oncol 2002; 41: 381-8.
6. Breslow NE, Day NE,. Statistical methods in cancer research, Vol 2. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987.
7. Hastie TJ, Tibshirani RJ,. Generalized additive models. London: Chapman & Hall, 1990.
8. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
9. Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping β-carotene and retinol supplements. J Natl Cancer Inst 2004; 96: 1743-50.
10. Gallicchio L, Boyd K, Matanoski G, et al. Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 2008; 88: 372-83.
11. Albanes D, Heinonen OP, Taylor PR, et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560-70.
12. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
13. Lee IM, Cook NR, Manson JE, et al. β-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91: 2102-6.
14. Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009; 101: 14-23.
15. Mayne ST, Handelman GJ, Beecher G,. β-Carotene and lung cancer promotion in heavy smokers- A plausible relationship? J Natl Cancer Inst 1996; 88: 1513-5.
16. Bendich A,. From 1989 to 2001: what have we learned about the "biological actions of beta-carotene"? J Nutr 2004; 134: 225S-30S.
17. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-9.
18. Leo MA, Lieber CS,. Alcohol, vitamin A, and β-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Am J Clin Nutr 1999; 69: 1071-85.
19. Parker RS,. Carotenoids in human blood and tissues. J Nutr 1989; 119: 101-4.
20. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-6.
21. Ju J, Picinich SC, Yang Z, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 2010; 31: 533-42.
22. Hartman TJ, Dorgan JF, Woodson K, et al. Effects of long-term α-tocopherol supplementation on serum hormones in older men. Prostate 2001; 46: 33-8.
23. The HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-47.
24. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II Randomized Controlled Trial. JAMA 2009; 301: 52-62.
25. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
26. Klein EA, Thompson IM, Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
27. Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 893-9.
28. Kirsh VA, Hayes RB, Mayne ST, et al, on behalf of the PLCO Trial. Supplemental and dietary vitamin E, β-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98: 245-54.
29. Weinstein SJ, Wright ME, Lawson KA, et al. Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 1253-9.
30. Weinstein SJ, Peters U, Ahn J, et al. Serum α-tocopherol and γ-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study. PLoS ONE 2012; 7: e40204.
31. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999; 59: 1225-30.
32. Key TJ, Appleby PN, Allen NE, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition Study. Am J Clin Nutr 2007; 86: 672-81.
33. Gill JK, Franke AA, Morris JS, et al. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F2t in serum or urine with prostate cancer risk: the Multiethnic Cohort. Cancer Causes Control 2009; 20: 1161-71.